Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.

NCT05751928 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05751928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05751928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 5, 2023
Completion date
June 30, 2027
Enrollment
411 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin), melanoma stage iii